References
- Salama NN, Segal JH, Churchwell MD et al. Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. Clin. J. Am. Soc. Nephrol.4, 1190–1194 (2009).
- Lysaght MJ. Maintenance dialysis population dynamics: current trends and long-term implications. J. Am. Soc. Nephrol.13(Suppl. 1), S37–S40 (2002).
- Amann K, Wanner C, Ritz E. Cross-talk between the kidney and the cardiovascular system. J. Am. Soc. Nephrol.17, 2112–2119 (2006).
- Sarnak MJ, Jaber BL. Pulmonary infectious mortality among patients with end-stage renal disease. Chest120, 1883–1887 (2001).
- Sarnak MJ, Jaber BL. Mortality caused by sepsis in patients with end-stage renal disease compared with the general population. Kidney Int.58, 1758–1764 (2000).
- Dalrymple LS, Go AS. Epidemiology of acute infections among patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol.3, 1487–1493 (2008).
- Chavers BM, Solid CA, Gilbertson DT, Collins AJ. Infection-related hospitalization rates in pediatric versus adult patients with end-stage renal disease in the United States. J. Am. Soc. Nephrol.18, 952–959 (2007).
- CDC. Invasive methicillin-resistant Staphylococcus aureus infections among dialysis patients – United States, 2005. MMWR Morb. Mortal. Wkly Rep.56, 197–199 (2007).
- Sader HS, Fritsche TR, Jones RN. Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients. Int. J. Infect. Dis.13, 291–295 (2009).
- Roveta S, Marchese A, Schito GC. Activity of daptomycin on biofilms produced on a plastic support by Staphylococcus spp. Int. J. Antimicrob. Agents31, 321–328 (2008).
- Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob. Agents Chemother.47, 1318–1323 (2003).
- Dvorchik B, Arbeit RD, Chung J, Liu S, Knebel W, Kastrissios H. Population pharmacokinetics of daptomycin. Antimicrob. Agents Chemother.48, 2799–2807 (2004).
- Kielstein JT, Oye C, Bode-Boeger SM et al. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis – a pharmacokinetic study. Nephrol. Dialysis Transplant. DOI: 10.1093/ndt/gfp704 (2009) (Epub ahead of print).
- Churchwell MD, Pasko DA, Mueller BA. Daptomycin clearance during modeled continuous renal replacement therapy. Blood Purif.24, 548–554 (2006).
- Goedecke VA, Clajus C, Burkhardt O et al. Pharmacokinetics and dialysate levels of daptomycin given intravenously in a peritoneal dialysis patient. Scand. J. Infect. Dis.41, 155–157 (2009).
- Huen SC, Hall I, Topal J, Mahnensmith RL, Brewster UC, Abu-Alfa AK. Successful use of intraperitoneal daptomycin in the treatment of vancomycin-resistant enterococcus peritonitis. Am. J. Kidney Dis.54, 538–541 (2009).
- Kielstein JT, Czock D, Schopke T et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit. Care Med.34, 51–56 (2006).
Website
- United States Renal Data System www.usrds.org